ERIC LEE NUERMBERGER, M.D.
Osteopathic Medicine at Eastern Ave, Baltimore, MD

License number
Maryland D56070
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Maryland D56070
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
4940 Eastern Ave, Baltimore, MD 21224
Phone
(410) 550-0501
(410) 933-4397

Personal information

See more information about ERIC LEE NUERMBERGER at radaris.com
Name
Address
Phone
Eric Nuermberger
1739 Circle Rd, Towson, MD 21204
Eric Nuermberger
1040 Deer Ridge Ln, Baltimore, MD 21210
Eric Nuermberger
11104 Worchester Dr, New Market, MD 21774
Eric Nuermberger
208 Woodlawn Ave, Baltimore, MD 21210

Professional information

See more information about ERIC LEE NUERMBERGER at trustoria.com
Eric L Nuermberger Photo 1
Dr. Eric L Nuermberger, Baltimore MD - MD (Doctor of Medicine)

Dr. Eric L Nuermberger, Baltimore MD - MD (Doctor of Medicine)

Specialties:
Infectious Disease Medicine
Address:
1550 Orleans St SUITE 107, Baltimore 21287
(410) 502-0580 (Phone), (410) 614-8173 (Fax)
4940 Eastern Ave, Baltimore 21224
(410) 550-0501 (Phone)
Baltimore Office
4940 Eastern Ave, Baltimore 21224
(410) 550-7900 (Phone), (410) 550-5961 (Fax)
BAYVIEW INTERNAL MEDICINE CLIN
4940 Eastern Ave, Baltimore 21224
(410) 550-3350 (Phone), (410) 550-5548 (Fax)
Certifications:
Infectious Disease, 2002, Internal Medicine, 1999
Awards:
Healthgrades Honor Roll
Languages:
English, Arabic
Hospitals:
1550 Orleans St SUITE 107, Baltimore 21287
4940 Eastern Ave, Baltimore 21224
Baltimore Office
4940 Eastern Ave, Baltimore 21224
BAYVIEW INTERNAL MEDICINE CLIN
4940 Eastern Ave, Baltimore 21224
Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore 21224
Education:
Medical School
Vanderbilt University
Graduated: 1996
Johns Hopkins Hospital


Eric Lee Nuermberger Photo 2
Eric Lee Nuermberger, Baltimore MD

Eric Lee Nuermberger, Baltimore MD

Specialties:
Internal Medicine, Infectious Disease, Pulmonary Disease
Work:
John Hopkins Medicine
4940 Eastern Ave, Baltimore, MD 21224 The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287
Education:
Vanderbilt University (1996)


Eric Lee Nuermberger Photo 3
Eric Lee Nuermberger, Baltimore MD

Eric Lee Nuermberger, Baltimore MD

Specialties:
Internist
Address:
1550 Orleans St, Baltimore, MD 21287
4940 Eastern Ave, Baltimore, MD 21224
Education:
Vanderbilt University, School of Medicine - Doctor of Medicine
Johns Hopkins Hospital - Fellowship - Infectious Disease (Internal Medicine)
Johns Hopkins Hospital - Residency - Internal Medicine
Johns Hopkins Hospital - Internship - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)


Eric Nuermberger Photo 4
Combination Therapy For Tuberculosis

Combination Therapy For Tuberculosis

US Patent:
2011019, Aug 4, 2011
Filed:
Aug 31, 2009
Appl. No.:
13/061233
Inventors:
Steven J. Brickner - Ledyard CT, US
Eric Nuermberger - Baltimore MD, US
Charles K. Stover - Gaithersburg MD, US
International Classification:
A61K 31/541, A61K 31/7036, A61K 31/606, A61K 38/12, A61P 31/06
US Classification:
514 29, 5142278, 514 35, 514161
Abstract:
The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (I), (S)—N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, (ii) a therapeutically effective amount of at least one agent useful in the treatment of tuberculosis and (iii) one or more pharmaceutically acceptable carriers or vehicles.